

**RESOLUTION #2—2023  
Regular Winter Session**

Submitted by  
Board of Directors

**SUPERSEDE POLICY ON THERAPEUTIC MEDICATIONS IN NON-RACING  
PERFORMANCE HORSES**

**RESOLVED** that the American Veterinary Medical Association (AVMA) House of Delegates adopt the policy on Therapeutic Medications in Competition Equids ([attachment 1](#)), which will supersede the policy on Therapeutic Medications in Non-racing Performance Horses ([attachment 2](#)).

**Statement about the Resolution**

In 2017, the AVMA Board of Directors (BOD) approved reaffirming endorsement of the American Association of Equine Practitioners (AAEP) policy on Therapeutic Medications in Non-racing Performance Horses. The review of this policy followed a 2021 review of the policy on [Therapeutic Medications in Racehorses](#). During that review the Animal Welfare Committee (AWC) recommended moving the policy from an endorsement to a standalone AVMA policy, which was a streamlined version of the 2020 AAEP policy. The AAEP and BOD agreed with these changes. The AWC took a similar approach to the performance horse policy and recommended that it become a standalone policy that is consistent with the AAEP policy. In 2020, the AAEP revised their policy on therapeutic medication use with several changes, notably moving from “performance horse” to “competition horse”. The AWC drafted the attached new policy. The drafted policy was shared with AAEP staff for review.

**Financial Impact: None**

	<b>Board of Directors</b>	<b>House Advisory Committee</b>	<b>Reference Committee #7</b>	<b>House of Delegates</b>
<b>Recommend Approval</b>	X	X	X	X
<b>Recommend Disapproval</b>				
<b>Recommend Referral to...</b>				
<b>No Recommendation</b>				
<b>Recommend Postpone Indefinitely</b>				
(use this space for additional narrative, if needed)				